0000869392-24-000126.txt : 20240125 0000869392-24-000126.hdr.sgml : 20240125 20240125131643 ACCESSION NUMBER: 0000869392-24-000126 CONFORMED SUBMISSION TYPE: NPORT-P PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20231130 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 PERIOD START: 20240831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM GLOBAL HEALTH CARE FUND CENTRAL INDEX KEY: 0000357295 ORGANIZATION NAME: IRS NUMBER: 046471950 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: NPORT-P SEC ACT: 1940 Act SEC FILE NUMBER: 811-03386 FILM NUMBER: 24560809 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 6177601000 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM HEALTH SCIENCES TRUST DATE OF NAME CHANGE: 19920703 0000357295 S000005666 PUTNAM GLOBAL HEALTH CARE FUND C000015515 Class A Shares PHSTX C000015516 Class B Shares PHSBX C000015517 Class C Shares PCHSX C000015519 Class R Shares PHSRX C000015520 Class Y Shares PHSYX C000221197 Class R6 Shares NPORT-P 1 primary_doc.xml NPORT-P false 0000357295 XXXXXXXX S000005666 C000015517 C000015515 C000015516 C000015519 C000015520 C000221197 Putnam Global Health Care Fund 811-03386 0000357295 549300O4L9RZ8L6RDS91 100 FEDERAL STREET BOSTON 02110 1-800-225-1581 Putnam Global Health Care Fund S000005666 549300O4L9RZ8L6RDS91 2024-08-31 2023-11-30 N 1590591918.95855 54628678.56855 1535963240.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5787.82 N MSCI World Health Care IDX00851 ABBVIE INC FR5LCKFTG8054YNNRU85 COMMON STOCK 00287Y109 641200 NS USD 91300468 5.944183141832 Long EC CORP US N 1 N N N DEXCOM INC 549300YSK3QDSFR5EU59 COMMON STOCK 252131107 558500 NS USD 64517920 4.200485942855 Long EC CORP US N 1 N N N IQVIA HOLDINGS INC 549300W3R20NM4KQPH86 COMMON STOCK 46266C105 110300 NS USD 23615230 1.537486664981 Long EC CORP US N 1 N N INNOVIVA INC 549300ACOX4QTBES6535 COMMON STOCK 45781M101 5157531 NS USD 71431804.35 4.650619394502 Long EC CORP US N 1 N N OPTION CARE HEALTH INC 549300DI3Q5ACSYJRI17 COMMON STOCK 68404L201 1196400 NS USD 35592900 2.317301551498 Long EC CORP US N 1 N N N HUMANA INC 529900YLDW34GJAO4J06 COMMON STOCK 444859102 72800 NS USD 35297808 2.298089372962 Long EC CORP US N 1 N N N MCKESSON CORP 549300WZWOM80UCFSF54 COMMON STOCK 58155Q103 95200 NS USD 44797312 2.916561465926 Long EC CORP US N 1 N N N INTUITIVE SURGICAL INC 54930052SRG011710797 COMMON STOCK 46120E602 270400 NS USD 84051136 5.472210127806 Long EC CORP US N 1 N N N JOHNSON AND JOHNSON 549300G0CFPGEF6X2043 COMMON STOCK 478160104 246943 NS USD 38192204.38 2.486531147080 Long EC CORP US N 1 N N N ELI LILLY AND CO FRDRIPF3EKNDJ2CQJL29 COMMON STOCK 532457108 175200 NS USD 103550208 6.741711342890 Long EC CORP US N 1 N N N REGENERON PHARMACEUTICALS INC 549300RCBFWIRX3HYQ56 COMMON STOCK 75886F107 41900 NS USD 34517639 2.247295904766 Long EC CORP US N 1 N N N STRYKER CORP 5493002F0SC4JTBU5137 COMMON STOCK 863667101 44900 NS USD 13305217 0.866245796131 Long EC CORP US N 1 N N N MERCK AND CO INC 4YV9Y5M8S0BRK1RP0397 COMMON STOCK 58933Y105 531538 NS USD 54472014.24 3.546439967285 Long EC CORP US N 1 N N N BOSTON SCIENTIFIC CORP Y6ZDD9FP4P8JSSJMW954 COMMON STOCK 101137107 1308600 NS USD 73137654 4.761679972330 Long EC CORP US N 1 N N N THERMO FISHER SCIENTIFIC INC HCHV7422L5HDJZCRFL38 COMMON STOCK 883556102 125500 NS USD 62217880 4.050740171633 Long EC CORP US N 1 N N N UNITEDHEALTH GROUP INC 549300GHBMY8T5GXDE41 COMMON STOCK 91324P102 287200 NS USD 158812984 10.339634427688 Long EC CORP US N 1 N N N DANAHER CORP S4BKK9OTCEWQ3YHPFM11 COMMON STOCK 235851102 214700 NS USD 47944657 3.121471643281 Long EC CORP US N 1 N N N BIOGEN INC W8J5WZB5IY3K0NDQT671 COMMON STOCK 09062X103 69900 NS USD 16362192 1.065272369139 Long EC CORP US N 1 N N N ROYALTY PHARMA PLC 549300FGFN7VOK8BZR03 COMMON STOCK G7709Q104 653600 NS USD 17692952 1.151912463446 Long EC CORP US N 1 N N N 4FRONT VENTURES CORP N/A COMMON STOCK 35086B207 49896829 NS USD 5887825.82 0.383331167386 Long EC CORP US N 1 N N N CIGNA GROUP/THE 549300VIWYMSIGT1U456 COMMON STOCK 125523100 139300 NS USD 36619184 2.384118515148 Long EC CORP US N 1 N N N ROCKET PHARMACEUTICALS INC 549300R7VV82YUIN4Y93 COMMON STOCK 77313F106 797600 NS USD 18608008 1.211487847540 Long EC CORP US N 1 N N N ASCENDIS PHARMA A/S 549300B66JN3W3J8GH73 COMMON STOCK - ADR 04351P101 572456 NS USD 57491756.08 3.743042448425 Long EC CORP DK N 1 N N LEGEND BIOTECH CORP 254900EIUFZTW136H859 COMMON STOCK - ADR N/A 113000 NS USD 6872660 0.447449510462 Long EC CORP US N 1 N N N JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 CURRENCY FORWARDS N/A 1 NC N/A 3291402.85 0.214289168090 N/A DFE CORP US N 2 JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 3247666.14 GBP 3291402.85 USD 2023-12-20 -43736.71 N N N GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 CURRENCY FORWARDS N/A 1 NC N/A 5715636.97 0.372120687507 N/A DFE CORP US N 2 GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 5638989.49 GBP 5715636.97 USD 2023-12-20 -76647.48 N N N BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 CURRENCY FORWARDS N/A 1 NC N/A 4656044.64 0.303135160892 N/A DFE CORP US N 2 BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 4596427.46 GBP 4656044.64 USD 2023-12-20 -59617.18 N N N BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 CURRENCY FORWARDS N/A 1 NC N/A 46913.25 0.003054321143 N/A DFE CORP US N 2 BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 46913.25 USD 44930.75 AUD 2024-01-17 1982.5 N N N NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 CURRENCY FORWARDS N/A 1 NC N/A 23355650.58 1.520586558704 N/A DFE CORP GB N 2 NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 23355650.58 USD 22356137.75 AUD 2024-01-17 999512.83 N N N MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 CURRENCY FORWARDS N/A 1 NC N/A 2598887.99 0.169202486209 N/A DFE CORP US N 2 MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 2598887.99 USD 2487726.63 AUD 2024-01-17 111161.36 N N N STATE STREET B AND T CO 571474TGEMMWANRLN572 CURRENCY FORWARDS N/A 1 NC N/A 1306117.99 0.085035758386 N/A DFE CORP US N 2 STATE STREET B AND T CO 571474TGEMMWANRLN572 1290191.92 CAD 1306117.99 USD 2024-01-17 -15926.07 N N N GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 CURRENCY FORWARDS N/A 1 NC N/A 1794492.55 0.116831738079 N/A DFE CORP US N 2 GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 1772745.82 CAD 1794492.55 USD 2024-01-17 -21746.73 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 2599255.93 0.169226441210 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 2567844.53 CAD 2599255.93 USD 2024-01-17 -31411.4 N N N JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 CURRENCY FORWARDS N/A 1 NC N/A 4855130.42 0.316096784892 N/A DFE CORP US N 2 JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 4795610.7 CAD 4855130.42 USD 2024-01-17 -59519.72 N N N GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 CURRENCY FORWARDS N/A 1 NC N/A 2212388.31 0.144039144416 N/A DFE CORP US N 2 GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 2212388.31 USD 2219117.03 ILS 2024-01-17 -6728.72 N N N WESTPAC BANKING CORPORATION EN5TNI6CI43VEPAMHL14 CURRENCY FORWARDS N/A 1 NC N/A 1657117.37 0.107887827418 N/A DFE CORP US N 2 WESTPAC BANKING CORPORATION EN5TNI6CI43VEPAMHL14 1657117.37 USD 1641847.81 EUR 2023-12-20 15269.56 N N N MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 CURRENCY FORWARDS N/A 1 NC N/A 6540673.76 0.425835305690 N/A DFE CORP US N 2 MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 6540673.76 USD 6389046.02 EUR 2023-12-20 151627.74 N N N TORONTO-DOMINION BANK/THE PT3QB789TSUIDF371261 CURRENCY FORWARDS N/A 1 NC N/A 4386954.91 0.285615878990 N/A DFE CORP CA N 2 TORONTO-DOMINION BANK/THE PT3QB789TSUIDF371261 4322225.82 EUR 4386954.91 USD 2023-12-20 -64729.09 N N N BARCLAYS BANK PLC WHOLESALE, LONDON G5GSEF7VJP5I7OUK5573 CURRENCY FORWARDS N/A 1 NC N/A 5130931.23 0.334052996522 N/A DFE CORP GB N 2 BARCLAYS BANK PLC WHOLESALE, LONDON G5GSEF7VJP5I7OUK5573 4982281.93 EUR 5130931.23 USD 2023-12-20 -148649.3 N N N STATE STREET B AND T CO 571474TGEMMWANRLN572 CURRENCY FORWARDS N/A 1 NC N/A 8440409.25 0.549518961655 N/A DFE CORP US N 2 STATE STREET B AND T CO 571474TGEMMWANRLN572 8366413.3 DKK 8440409.25 USD 2023-12-20 -73995.95 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 5328173.47 0.346894595514 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 5328173.47 USD 5169640.01 DKK 2023-12-20 158533.46 N N N CITIBANK N.A. E57ODZWZ7FF32TWEFA76 CURRENCY FORWARDS N/A 1 NC N/A 32833816.31 2.137669408134 N/A DFE CORP US N 2 CITIBANK N.A. E57ODZWZ7FF32TWEFA76 32540701.22 DKK 32833816.31 USD 2023-12-20 -293115.09 N N N NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 CURRENCY FORWARDS N/A 1 NC N/A 102854.11 0.006696391378 N/A DFE CORP GB N 2 NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 102854.11 USD 13432.56 DKK 2023-12-20 89421.55 N N N UBS AG BFM8T61CT2L1QCEMIK50 CURRENCY FORWARDS N/A 1 NC N/A 8400278.9 0.546906246133 N/A DFE CORP US N 2 UBS AG BFM8T61CT2L1QCEMIK50 8326517.77 DKK 8400278.9 USD 2023-12-20 -73761.13 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 41688756.91 2.714176733775 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 41688756.91 USD 41400806.41 CHF 2023-12-20 287950.5 N N N BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 CURRENCY FORWARDS N/A 1 NC N/A 41511091.17 2.702609677004 N/A DFE CORP US N 2 BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 41511091.17 USD 41212100.56 CHF 2023-12-20 298990.61 N N N UBS AG BFM8T61CT2L1QCEMIK50 CURRENCY FORWARDS N/A 1 NC N/A 1480357.17 0.096379726485 N/A DFE CORP US N 2 UBS AG BFM8T61CT2L1QCEMIK50 1480357.17 USD 1470371 CHF 2023-12-20 9986.17 N N N MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 CURRENCY FORWARDS N/A 1 NC N/A 5331001.82 0.347078737291 N/A DFE CORP US N 2 MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 5331001.82 USD 5333433.85 CHF 2023-12-20 -2432.03 N N N STATE STREET B AND T CO 571474TGEMMWANRLN572 CURRENCY FORWARDS N/A 1 NC N/A 20071995.81 1.306801834978 N/A DFE CORP US N 2 STATE STREET B AND T CO 571474TGEMMWANRLN572 20071995.81 USD 19937840.56 CHF 2023-12-20 134155.25 N N N WESTPAC BANKING CORPORATION EN5TNI6CI43VEPAMHL14 CURRENCY FORWARDS N/A 1 NC N/A 2589595.43 0.168597487355 N/A DFE CORP US N 2 WESTPAC BANKING CORPORATION EN5TNI6CI43VEPAMHL14 2589595.43 USD 2574408.32 CHF 2023-12-20 15187.11 N N N UBS AG BFM8T61CT2L1QCEMIK50 CURRENCY FORWARDS N/A 1 NC N/A 903846.58 0.058845586680 N/A DFE CORP US N 2 UBS AG BFM8T61CT2L1QCEMIK50 903846.58 USD 897779.61 JPY 2024-02-21 6066.97 N N N JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 CURRENCY FORWARDS N/A 1 NC N/A 4126020.71 0.268627568779 N/A DFE CORP US N 2 JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 4126020.71 USD 4093353.12 JPY 2024-02-21 32667.59 N N N GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 CURRENCY FORWARDS N/A 1 NC N/A 16247746.5 1.057821311913 N/A DFE CORP US N 2 GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 16247746.5 USD 16122463.09 JPY 2024-02-21 125283.41 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 7643913.18 0.497662507734 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 7542212.44 GBP 7643913.18 USD 2023-12-20 -101700.74 N N N BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 CURRENCY FORWARDS N/A 1 NC N/A 3270336.88 0.212917652845 N/A DFE CORP US N 2 BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 3270336.88 USD 3193688.52 EUR 2023-12-20 76648.36 N N N MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 CURRENCY FORWARDS N/A 1 NC N/A 2222845.91 0.144719994043 N/A DFE CORP US N 2 MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 2275725.78 GBP 2222845.91 USD 2023-12-20 52879.87 N N N ARGENX SE 7245009C5FZE6G9ODQ71 ORDINARY SHARES N/A 21781 NS 9738301.71 0.634019190949 Long EC CORP NL N 2 N N N TERRASCEND CORP 529900Z66HBZ5381EO49 ORDINARY SHARES 88105E108 5980632 NS USD 9569011.2 0.622997409598 Long EC CORP CA N 1 N N NOVO NORDISK A/S 549300DAQ1CVT6CXN342 ORDINARY SHARES N/A 708982 NS 72167700.3 4.698530433689 Long EC CORP DK N 2 N N N EISAI CO LTD 353800HDEE0ZYEX4QV91 ORDINARY SHARES N/A 109300 NS 5655939.57 0.368234045013 Long EC CORP JP N 1 N N N TAKEDA PHARMACEUTICAL CO LTD 549300ZLMVP4X0OGR454 ORDINARY SHARES J81281115 603800 NS 16962275.73 1.104341255308 Long EC CORP JP N 1 N N N ASTRAZENECA PLC PY6ZZQWO2IZFZC3IOL08 ORDINARY SHARES N/A 665729 NS 85181918.71 5.545830555709 Long EC CORP GB N 2 N N N SANOFI SA 549300E9PC51EN656011 ORDINARY SHARES N/A 745667 NS 69459123.53 4.522186579958 Long EC CORP FR N 2 N N N TERUMO CORPORATION 353800JX1R4582QVK932 ORDINARY SHARES N/A 141900 NS 4515609.07 0.293992001322 Long EC CORP JP N 1 N N N DAIICHI SANKYO CO LTD 353800XGIU2IHQGC9504 ORDINARY SHARES N/A 541100 NS 14598678 0.950457512010 Long EC CORP JP N 1 N N N PUTNAM SHORT TERM INVESTMENT FUND 5493003MK0Q7JP8CPP42 SHORT TERM INV FUND 74676P664 27206750 NS USD 27206750 1.771315177640 Long STIV PF US N 2 N N N PUTNAM CASH COLLATERAL POOL LLC 5493005HRIV7IFMKD774 SHORT TERM INV FUND N/A 48644328 NS USD 48644328 3.167024230843 Long STIV PF US N 2 N N State Street Institutional U.S. Government Money Market Fund, Premier Class N/A SHORT TERM INV FUND N/A 430000 NS USD 430000 0.027995461655 Long STIV RF US N 1 N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T BILLS 912797JA6 1000000 PA USD 992243.23 0.064600714647 Long DBT UST US N 2 2024-01-23 Fixed 0 N N N N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T BILLS 912797FT9 2800000 PA USD 2797537.68 0.182135718254 Long DBT UST US N 2 2023-12-07 Fixed 0 N N N N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T. NOTE 91282CHU8 326000 PA USD 329026.70788 0.021421522288 Long DBT UST US N 2 2026-08-15 Fixed 4.375 N N N N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T. NOTE 91282CCR0 240000 PA USD 207192 0.013489385328 Long DBT UST US N 2 2028-07-31 Fixed 1 N N N N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T. NOTE 912828U24 759000 PA USD 708509.90067 0.046128050596 Long DBT UST US N 2 2026-11-15 Fixed 2 N N N N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T. NOTE 912828P46 406000 PA USD 382565.68 0.024907215872 Long DBT UST US N 2 2026-02-15 Fixed 1.625 N N N N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T. NOTE 91282CCB5 463000 PA USD 384072.39 0.025005311319 Long DBT UST US N 2 2031-05-15 Fixed 1.625 N N N N N N 2024-01-25 Putnam Investments Inc Janet C. Smith NPORT Principal Financial Officer XXXX NPORT-EX 2 b_021nport113023.htm QUARTERLY PORTFOLIO HOLDINGS
Putnam Global Health Care Fund
The fund's portfolio
11/30/23 (Unaudited)


COMMON STOCKS (96.6%)(a)
        Shares Value
Biotechnology (15.2%)
AbbVie, Inc. 641,200 $91,300,468
Argenx SE (Netherlands)(NON) 21,781 9,738,302
Ascendis Pharma A/S ADR (Denmark)(NON)(S) 572,456 57,491,756
Biogen, Inc.(NON) 69,900 16,362,192
Legend Biotech Corp. ADR(NON) 113,000 6,872,660
Regeneron Pharmaceuticals, Inc.(NON) 41,900 34,517,639
Rocket Pharmaceuticals, Inc.(NON) 797,600 18,608,008

234,891,025
Health care equipment and supplies (15.6%)
Boston Scientific Corp.(NON) 1,308,600 73,137,654
Dexcom, Inc.(NON) 558,500 64,517,920
Intuitive Surgical, Inc.(NON) 270,400 84,051,136
Stryker Corp. 44,900 13,305,217
Terumo Corp. (Japan) 141,900 4,515,609

239,527,536
Health care providers and services (20.3%)
Cigna Group (The) 139,300 36,619,184
Humana, Inc. 72,800 35,297,808
McKesson Corp. 95,200 44,797,312
Option Care Health, Inc.(NON) 1,196,400 35,592,900
UnitedHealth Group, Inc. 287,200 158,812,984

311,120,188
Life sciences tools and services (8.7%)
Danaher Corp. 214,700 47,944,657
IQVIA Holdings, Inc.(NON)(S) 110,300 23,615,230
Thermo Fisher Scientific, Inc. 125,500 62,217,880

133,777,767
Pharmaceuticals (36.8%)
4Front Ventures Corp.(NON)(AFF) 49,896,829 5,887,826
AstraZeneca PLC (United Kingdom) 665,729 85,181,919
Daiichi Sankyo Co., Ltd. (Japan) 541,100 14,598,678
Eisai Co., Ltd. (Japan) 109,300 5,655,940
Eli Lilly and Co. 175,200 103,550,208
Innoviva, Inc.(NON)(S)(AFF) 5,157,531 71,431,804
Johnson & Johnson 246,943 38,192,204
Merck & Co., Inc. 531,538 54,472,014
Novo Nordisk A/S Class B (Denmark) 708,982 72,167,700
Royalty Pharma PLC Class A 653,600 17,692,952
SANOFI SA (France) 745,667 69,459,124
Takeda Pharmaceutical Co., Ltd. (Japan) 603,800 16,962,276
TerrAscend Corp. (Canada)(NON)(S) 5,846,328 9,354,124

564,606,769

Total common stocks (cost $1,055,893,558) $1,483,923,285









U.S. TREASURY OBLIGATIONS (0.1%)(a)
        Principal amount Value
U.S. Treasury Notes
4.375%, 8/15/26(i) $326,000 $329,027
2.00%, 11/15/26(i) 759,000 708,510
1.625%, 5/15/31(i) 463,000 384,072
1.625%, 2/15/26(i) 406,000 382,566
1.00%, 7/31/28(i) 240,000 207,192

Total U.S. treasury obligations (cost $2,011,367) $2,011,367









SHORT-TERM INVESTMENTS (5.2%)(a)
        Principal amount/shares Value
Putnam Cash Collateral Pool, LLC 5.58%(AFF) Shares 48,644,328 $48,644,328
Putnam Short Term Investment Fund Class P 5.57%(AFF) Shares 27,206,750 27,206,750
State Street Institutional U.S. Government Money Market Fund, Premier Class 5.31%(P) Shares 430,000 430,000
U.S. Treasury Bills 5.432%, 1/23/24(SEGSF) $1,000,000 992,243
U.S. Treasury Bills 5.424%, 12/7/23(SEGSF) 2,800,000 2,797,538

Total short-term investments (cost $80,070,845) $80,070,859
TOTAL INVESTMENTS

Total investments (cost $1,137,975,770) $1,566,005,511









FORWARD CURRENCY CONTRACTS at 11/30/23 (aggregate face value $268,823,678) (Unaudited)
  Counterparty Currency Contract type* Delivery
date
Value Aggregate face value Unrealized
appreciation/
(depreciation)
Bank of America N.A.
Australian Dollar Buy 1/17/24 $46,913 $44,931 $1,982
British Pound Sell 12/20/23 4,656,045 4,596,427 (59,618)
Euro Buy 12/20/23 3,270,337 3,193,689 76,648
Swiss Franc Buy 12/20/23 41,511,091 41,212,101 298,990
Barclays Bank PLC
Euro Sell 12/20/23 5,130,931 4,982,282 (148,649)
Citibank, N.A.
Danish Krone Sell 12/20/23 32,833,816 32,540,701 (293,115)
Goldman Sachs International
British Pound Sell 12/20/23 5,715,637 5,638,989 (76,648)
Canadian Dollar Sell 1/17/24 1,794,493 1,772,746 (21,747)
Israeli Shekel Buy 1/17/24 2,212,388 2,219,117 (6,729)
Japanese Yen Buy 2/21/24 16,247,747 16,122,463 125,284
HSBC Bank USA, National Association
British Pound Sell 12/20/23 7,643,913 7,542,212 (101,701)
Canadian Dollar Sell 1/17/24 2,599,256 2,567,845 (31,411)
Danish Krone Buy 12/20/23 5,328,173 5,169,640 158,533
Swiss Franc Buy 12/20/23 41,688,757 41,400,806 287,951
JPMorgan Chase Bank N.A.
British Pound Sell 12/20/23 3,291,403 3,247,666 (43,737)
Canadian Dollar Sell 1/17/24 4,855,130 4,795,611 (59,519)
Japanese Yen Buy 2/21/24 4,126,021 4,093,353 32,668
Morgan Stanley & Co. International PLC
Australian Dollar Buy 1/17/24 2,598,888 2,487,727 111,161
British Pound Sell 12/20/23 2,222,846 2,275,726 52,880
Euro Buy 12/20/23 6,540,674 6,389,046 151,628
Swiss Franc Buy 12/20/23 5,331,002 5,333,433 (2,431)
NatWest Markets PLC
Australian Dollar Buy 1/17/24 23,355,651 22,356,138 999,513
Danish Krone Buy 12/20/23 102,854 13,432 89,422
State Street Bank and Trust Co.
Canadian Dollar Sell 1/17/24 1,306,118 1,290,192 (15,926)
Danish Krone Sell 12/20/23 8,440,409 8,366,413 (73,996)
Swiss Franc Buy 12/20/23 20,071,996 19,937,841 134,155
Toronto-Dominion Bank
Euro Sell 12/20/23 4,386,955 4,322,226 (64,729)
UBS AG
Danish Krone Sell 12/20/23 8,400,279 8,326,518 (73,761)
Japanese Yen Buy 2/21/24 903,847 897,780 6,067
Swiss Franc Buy 12/20/23 1,480,357 1,470,371 9,986
WestPac Banking Corp.
Euro Buy 12/20/23 1,657,117 1,641,848 15,269
Swiss Franc Buy 12/20/23 2,589,596 2,574,408 15,188

Unrealized appreciation 2,567,325

Unrealized (depreciation) (1,073,717)

Total $1,493,608
* The exchange currency for all contracts listed is the United States Dollar.













Key to holding's abbreviations
ADR American Depository Receipts: Represents ownership of foreign securities on deposit with a custodian bank.
Notes of the fund's portfolio
Unless noted otherwise, the notes of the fund's portfolio are for the close of the fund's reporting period, which ran from September 1, 2023 through November 30, 2023 (the reporting period). Within the following notes to the portfolio, references to "Putnam Management" represent Putnam Investment Management, LLC, the fund's manager, an indirect wholly-owned subsidiary of Franklin Resources, Inc., references to "ASC 820" represent Accounting Standards Codification 820 Fair Value Measurements and Disclosures and references to "OTC", if any, represent over-the-counter.
(a) Percentages indicated are based on net assets of $1,535,553,449.
(NON) This security is non-income-producing.
(AFF) Affiliated company. For investments in Putnam Cash Collateral Pool, LLC and Putnam Short Term Investment Fund, the rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period. Transactions during the period with any company which is under common ownership or control, or involving securities of companies in which the fund owned at least 5% of the outstanding voting securities, were as follows:
Name of affiliate Fair value
as of
8/31/23
Purchase
cost
Sale
proceeds
Investment
income
Change in unrealized appreciation (depreciation) Shares outstanding at period end Fair value
as of
11/30/23
Short-term investments
Putnam Cash Collateral Pool, LLC*# $50,451,765 $54,666,636 $56,474,074 $674,996 $— 48,644,328 $48,644,328
Putnam Short Term Investment Fund** 84,847,718 48,826,215 106,467,183 682,148 27,206,750 27,206,750






Total Short-term investments 135,299,483 103,492,851 162,941,257 1,357,144 75,851,078
Common stocks***
Health care
4Front Ventures Corp. 6,336,897 (449,071) 49,896,829 5,887,826
Innoviva, Inc. 65,758,520 5,673,284 5,157,531 71,431,804






Total Common stocks 72,095,417 5,224,213 77,319,630






Totals $207,394,900 $103,492,851 $162,941,257 $1,357,144 $5,224,213 $153,170,708
* The fund may lend securities, through its agent, to qualified borrowers in order to earn additional income. The loans are collateralized by cash in an amount at least equal to the fair value of the securities loaned. The fair value of securities loaned is determined daily and any additional required collateral is allocated to the fund on the next business day. The remaining maturities of the securities lending transactions are considered overnight and continuous. The risk of borrower default will be borne by the fund’s agent; the fund will bear the risk of loss with respect to the investment of the cash collateral. The fund receives cash collateral, which is invested in Putnam Cash Collateral Pool, LLC, a limited liability company managed by an affiliate of Putnam Management. Investments in Putnam Cash Collateral Pool, LLC are valued at its closing net asset value each business day. There are no management fees charged to Putnam Cash Collateral Pool, LLC and there were no realized or unrealized gains or losses during the period.
# At the close of the reporting period, the fund received cash collateral of $49,114,580 for securities loaned. The rate quoted in the security description is the annualized 7-day yield at the close of the reporting period. At the close of the reporting period, the value of securities loaned amounted to $48,644,328.
** Management fees charged to Putnam Short Term Investment Fund have been waived by Putnam Management. There were no realized or unrealized gains or losses during the period.
*** Common stock classifications are presented at the sector level, which may differ from the fund's portfolio presentation.
(SEGSF) This security, in part or in entirety, was pledged and segregated with the custodian for collateral on certain derivative contracts at the close of the reporting period. Collateral at period end totaled $949,180.
(i) This security was pledged, or purchased with cash that was pledged, to the fund for collateral on certain derivative contracts.
(P) This security was pledged, or purchased with cash that was pledged, to the fund for collateral on certain derivative contracts. The rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period.
(S) This security is on loan, in part or in entirety, at the close of the reporting period.
Unless otherwise noted, the rates quoted in Short-term investments security descriptions represent the weighted average yield to maturity.
The dates shown on debt obligations are the original maturity dates.
DIVERSIFICATION BY COUNTRY
Distribution of investments by country of risk at the close of the reporting period, excluding collateral received, if any (as a percentage of Portfolio Value):
United States 77.2%
Denmark 8.6
United Kingdom 5.6
France 4.6
Japan 2.8
Netherlands 0.6
Canada 0.6

Total 100.0%
Methodology differs from that used for purposes of complying with the fund’s policy regarding investments in securities of foreign issuers, as discussed further in the fund’s prospectus.
Security valuation: Portfolio securities and other investments are valued using policies and procedures adopted by the Board of Trustees. The Trustees have formed a Pricing Committee to oversee the implementation of these procedures and have delegated responsibility for valuing the fund’s assets in accordance with these procedures to Putnam Management. Putnam Management has established an internal Valuation Committee that is responsible for making fair value determinations, evaluating the effectiveness of the pricing policies of the fund and reporting to the Pricing Committee.
Investments for which market quotations are readily available are valued at the last reported sales price on their principal exchange, or official closing price for certain markets, and are classified as Level 1 securities under ASC 820. If no sales are reported, as in the case of some securities that are traded OTC, a security is valued at its last reported bid price and is generally categorized as a Level 2 security.
Investments in open-end investment companies (excluding exchange-traded funds), if any, which can be classified as Level 1 or Level 2 securities, are valued based on their net asset value. The net asset value of such investment companies equals the total value of their assets less their liabilities and divided by the number of their outstanding shares.
Market quotations are not considered to be readily available for certain debt obligations (including short-term investments with remaining maturities of 60 days or less) and other investments; such investments are valued on the basis of valuations furnished by an independent pricing service approved by the Trustees or dealers selected by Putnam Management. Such services or dealers determine valuations for normal institutional-size trading units of such securities using methods based on market transactions for comparable securities and various relationships, generally recognized by institutional traders, between securities (which consider such factors as security prices, yields, maturities and ratings). These securities will generally be categorized as Level 2.
Many securities markets and exchanges outside the U.S. close prior to the scheduled close of the New York Stock Exchange and therefore the closing prices for securities in such markets or on such exchanges may not fully reflect events that occur after such close but before the scheduled close of the New York Stock Exchange. Accordingly, on certain days, the fund will fair value certain foreign equity securities taking into account multiple factors including movements in the U.S. securities markets, currency valuations and comparisons to the valuation of American Depository Receipts, exchange-traded funds and futures contracts. The foreign equity securities, which would generally be classified as Level 1 securities, will be transferred to Level 2 of the fair value hierarchy when they are valued at fair value. The number of days on which fair value prices will be used will depend on market activity and it is possible that fair value prices will be used by the fund to a significant extent. At the close of the reporting period, fair value pricing was used for certain foreign securities in the portfolio. Securities quoted in foreign currencies, if any, are translated into U.S. dollars at the current exchange rate.
To the extent a pricing service or dealer is unable to value a security or provides a valuation that Putnam Management does not believe accurately reflects the security's fair value, the security will be valued at fair value by Putnam Management, which has been designated as valuation designee pursuant to Rule 2a-5 under the Investment Company Act of 1940, in accordance with policies and procedures approved by the Trustees. Certain investments, including certain restricted and illiquid securities and derivatives, are also valued at fair value following procedures approved by the Trustees. These valuations consider such factors as significant market or specific security events such as interest rate or credit quality changes, various relationships with other securities, discount rates, U.S. Treasury, U.S. swap and credit yields, index levels, convexity exposures, recovery rates, sales and other multiples and resale restrictions. These securities are classified as Level 2 or as Level 3 depending on the priority of the significant inputs.
To assess the continuing appropriateness of fair valuations, the Valuation Committee reviews and affirms the reasonableness of such valuations on a regular basis after considering all relevant information that is reasonably available. Such valuations and procedures are reviewed periodically by the Trustees. The fair value of securities is generally determined as the amount that the fund could reasonably expect to realize from an orderly disposition of such securities over a reasonable period of time. By its nature, a fair value price is a good faith estimate of the value of a security in a current sale and does not reflect an actual market price, which may be different by a material amount.
Forward currency contracts: The fund buys and sells forward currency contracts, which are agreements between two parties to buy and sell currencies at a set price on a future date. These contracts were used to hedge foreign exchange risk.
The U.S. dollar value of forward currency contracts is determined using current forward currency exchange rates supplied by a quotation service. The fair value of the contract will fluctuate with changes in currency exchange rates. The contract is marked to market daily and the change in fair value is recorded as an unrealized gain or loss. The fund records a realized gain or loss equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed when the contract matures or by delivery of the currency. The fund could be exposed to risk if the value of the currency changes unfavorably, if the counterparties to the contracts are unable to meet the terms of their contracts or if the fund is unable to enter into a closing position.
For the fund's average contract amount on forward currency contracts, see the appropriate table at the end of these footnotes.
Master agreements: The fund is a party to ISDA (International Swaps and Derivatives Association, Inc.) Master Agreements (Master Agreements) with certain counterparties that govern OTC derivative and foreign exchange contracts entered into from time to time. The Master Agreements may contain provisions regarding, among other things, the parties’ general obligations, representations, agreements, collateral requirements, events of default and early termination. With respect to certain counterparties, in accordance with the terms of the Master Agreements, collateral posted to the fund is held in a segregated account by the fund’s custodian and, with respect to those amounts which can be sold or repledged, is presented in the fund’s portfolio.
Collateral pledged by the fund is segregated by the fund’s custodian and identified in the fund’s portfolio. Collateral can be in the form of cash or debt securities issued by the U.S. Government or related agencies or other securities as agreed to by the fund and the applicable counterparty. Collateral requirements are determined based on the fund’s net position with each counterparty.
Termination events applicable to the fund may occur upon a decline in the fund’s net assets below a specified threshold over a certain period of time. Termination events applicable to counterparties may occur upon a decline in the counterparty’s long-term and short-term credit ratings below a specified level. In each case, upon occurrence, the other party may elect to terminate early and cause settlement of all derivative and foreign exchange contracts outstanding, including the payment of any losses and costs resulting from such early termination, as reasonably determined by the terminating party. Any decision by one or more of the fund’s counterparties to elect early termination could impact the fund’s future derivative activity.
At the close of the reporting period, the fund had a net liability position of $634,789 on open derivative contracts subject to the Master Agreements. Collateral posted by the fund at period end for these agreements totaled $949,180 and may include amounts related to unsettled agreements.









ASC 820 establishes a three-level hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of the fund's investments. The three levels are defined as follows:
Level 1: Valuations based on quoted prices for identical securities in active markets.
Level 2: Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
Level 3: Valuations based on inputs that are unobservable and significant to the fair value measurement.
The following is a summary of the inputs used to value the fund's net assets as of the close of the reporting period:
  Valuation inputs
Investments in securities: Level 1 Level 2 Level 3
Common stocks*:
Health care $1,247,376,240 $236,547,045 $—



Total common stocks 1,247,376,240 236,547,045
U.S. treasury obligations 2,011,367
Short-term investments 430,000 79,640,859



Totals by level $1,247,806,240 $318,199,271 $—
  Valuation inputs
Other financial instruments: Level 1 Level 2 Level 3
Forward currency contracts $— $1,493,608 $—



Totals by level $— $1,493,608 $—
* Common stock classifications are presented at the sector level, which may differ from the fund's portfolio presentation.
The volume of activity for the reporting period for any derivative type that was held at the close of the period is listed below and was based on an average of the holdings of that derivative at the end of each fiscal quarter in the reporting period:
Forward currency contracts (contract amount) $325,900,000
For additional information regarding the fund please see the fund's most recent annual or semiannual shareholder report filed on the Securities and Exchange Commission's Web site, www.sec.gov, or visit Putnam's Individual Investor Web site at www.putnaminvestments.com